CAPR
Capricor Therapeutics, Inc.
$5.74
-0.19
(-3.20%)
Mkt Cap
332.41M
Volume
1,537,435
52W Range
2.96-40.37
Sector
Healthcare
Beta
0.53
EPS (TTM)
-2.45 USD
P/E Ratio
-12.77
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.27M | 25.18M | 2.55M | 244,898 | 310,250 | 1.01M | 1.67M | 2.67M | 3.19M | 3.78M | 4.17M |
| Net Income | (105.04M) | (40.47M) | (22.29M) | (29.02M) | (20.02M) | (13.66M) | (7.64M) | (15.19M) | 2.43M | (18.81M) | (12.86M) | (6.22M) |
| EPS | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 |
| Free Cash Flow | (72.72M) | (41.53M) | (27.64M) | 1.56M | (18.01M) | (10.60M) | (6.82M) | (14.18M) | (14.26M) | (16.00M) | (10.97M) | 772,131 |
| FCF / Share | -1.56 | -1.18 | -1.03 | 0.06 | -0.78 | -0.68 | -1.84 | -4.83 | -6.15 | -8.62 | -6.90 | 0.66 |
| Operating CF | (69.81M) | (40.00M) | (25.60M) | 4.92M | (16.81M) | (10.05M) | (6.82M) | (13.86M) | (14.23M) | (15.80M) | (10.82M) | 958,562 |
| Total Assets | 355.95M | 170.48M | 58.73M | 50.09M | 41.33M | 34.62M | 11.11M | 9.25M | 16.27M | 18.75M | 16.07M | 13.63M |
| Total Debt | 17.94M | 4.83M | 5.61M | 5.94M | 6.25M | 3.69M | 3.38M | 3.38M | 3.38M | 17.01M | 9.16M | 9.16M |
| Cash & Equiv | 287.85M | 11.29M | 14.69M | 9.60M | 34.89M | 32.67M | 3.90M | 4.26M | 6.14M | 3.20M | 5.57M | 8.03M |
| Book Value | 305.79M | 145.46M | 22.60M | 11.79M | 31.37M | 28.20M | 6.84M | 4.62M | 11.23M | (4.00M) | (1.03M) | (6.25M) |
| Return on Equity | -0.34 | -0.28 | -0.99 | -2.46 | -0.64 | -0.48 | -1.12 | -3.29 | 0.22 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M | 6.19M |
| Net Income | (40.73M) | (33.94M) | (30.17M) | (24.57M) | (25.91M) | (24.39M) | (7.12M) | (12.56M) | (11.00M) | (9.79M) | (762,089) | (6.39M) |
| EPS | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 | -0.25 |
| Free Cash Flow | (37.39M) | (40.00M) | (28.69M) | (23.70M) | (21.57M) | (7.57M) | (15.53M) | (11.70M) | (12.37M) | (1.93M) | (12.32M) | (9.43M) |
| FCF / Share | -0.65 | -0.70 | -0.59 | -0.52 | -0.47 | -0.17 | -0.44 | -0.35 | -0.39 | -0.06 | -0.46 | -0.37 |
| Operating CF | (31.49M) | (29.25M) | (23.57M) | (19.69M) | (20.12M) | (6.43M) | (14.80M) | (11.64M) | (12.29M) | (1.27M) | (11.59M) | (8.79M) |
| Total Assets | 368.74M | 326.28M | 355.95M | 126.44M | 133.57M | 153.77M | 170.48M | 92.95M | 38.28M | 49.44M | 58.73M | 37.15M |
| Total Debt | 91.05M | 21.12M | 17.94M | 17.92M | 4.42M | 4.63M | 4.83M | 5.02M | 5.21M | 5.40M | 5.61M | 5.79M |
| Cash & Equiv | 20.94M | 105.42M | 287.85M | 19.51M | 23.24M | 28.79M | 11.29M | 68.38M | 10.69M | 6.21M | 14.69M | 8.98M |
| Book Value | 246.22M | 278.70M | 305.79M | 83.87M | 104.98M | 127.65M | 145.46M | 68.26M | 11.50M | 18.43M | 22.60M | (1.79M) |
| Return on Equity | -0.17 | -0.12 | -0.10 | -0.29 | -0.25 | -0.19 | -0.05 | -0.18 | -0.96 | -0.53 | -0.03 | N/A |
CAPR News
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
Inflation Breather Could Help Stocks Finish Q3 Strong
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR